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Abstract
Nipah virus targets human endothelial cells via NiV-F and NiV-G envelope glycoproteins, resulting in endothelial syncytia
formation and vascular compromise. Endothelial cells respond to viral infection by releasing innate immune effectors,
including galectins, which are secreted proteins that bind to specific glycan ligands on cell surface glycoproteins. We
demonstrate that galectin-1 reduces NiV-F mediated fusion of endothelial cells, and that endogenous galectin-1 in
endothelial cells is sufficient to inhibit syncytia formation. Galectin-1 regulates NiV-F mediated cell fusion at three distinct
points, including retarding maturation of nascent NiV-F, reducing NiV-F lateral mobility on the plasma membrane, and
directly inhibiting the conformational change in NiV-F required for triggering fusion. Characterization of the NiV-F N-
glycome showed that the critical site for galectin-1 inhibition is rich in glycan structures known to bind galectin-1. These
studies identify a unique set of mechanisms for regulating pathophysiology of NiV infection at the level of the target cell.
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Introduction
Nipah virus (NiV) is a lethal emerging virus that infects
agricultural livestock and humans. In 1999–2000, NiV infection of
agricultural workers in Malaysia and Singapore resulted in a 40%
mortality rate, and subsequent outbreaks in Bangladesh resulted in
an average case-fatality ratio greater than 70% [1]. In humans,
NiV targets endothelial and neural cells, with resulting respiratory
and neurologic sequelae; patients infected with Nipah virus often
succumb to acute encephalitis with accompanying multi-organ
failure due to systemic vasculitis. Autopsy studies of NiV victims
identified virus in endothelial cells, with endothelial cell syncytia
formation being a pathognomonic hallmark of NiV infection
[2,3,4].
NiV, a member of a new genus of Paramyxoviridae,i sa n
enveloped virus with two viral envelope glycoproteins, NiV-G
and NiV-F, that mediate viral entry [5]. The NiV-G attachment
glycoprotein binds to specific receptors, primarily ephrinB2 or
alternatively ephrinB3 [6,7,8]. While ephrinB2 and ephrinB3 are
expressed in neuronal cells, only ephrinB2 is highly expressed on
endothelial cells [9]. The NiV-F glycoprotein mediates fusion of
bound virus with target cells. After endothelial cell infection,
NiV-F and NiV-G glycoproteins are expressed on the surface of
infected cells. This triggers cell-cell fusion with neighboring
endothelial cells (homologous fusion) or stromal cells (heterolo-
gous fusion), resulting in endothelial syncytia formation, endo-
thelial disruption, and subsequent hemorrhage and tissue
damage.
The NiV-F fusion glycoprotein, NiV-F0, is initially expressed
at the cell surface as a single glycosylated polypeptide precursor,
but subsequently undergoes endocytosis and endosomal proteo-
lytic cleavage by cathepsin L into F1 and F2 subunits that are
disulfide linked to form the mature fusion protein NiV-F1/2
[10,11,12]. Mature NiV-F traffics back to the cell surface, where
the protein can initiate cell-cell fusion at neutral pH when it is
appropriately triggered by receptor binding to NiV-G. Our labs
and others have previously demonstrated that specific N-glycans
on NiV-F play important roles in regulating the extent of cell
fusion [13,14].
Infection of endothelial cells by viruses results in the release of
innate immune effectors, including galectins, a family of
mammalian lectins [15,16]. Galectins are soluble, secreted
proteins that stay associated with the cell surface by binding
specific cell surface glycan ligands on specific glycoprotein
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multimers, and can thus cross-link glycan ligands and the
glycoprotein receptors that bear these ligands on the surface of
cells. Human endothelial cells express galectin-1, as well as
galectin-3, -8, and -9, and in vitro and in vivo activation of human
endothelial cells increased synthesis as well as secretion and cell
surface localization of galectin-1 [17,18,19].
We have previously shown that recombinant human galectin-1
inhibits cell fusion and syncytia formation caused by NiV-F [20].
The mechanism by which galectin-1 inhibits NiV-F mediated cell
fusion is not well understood; however, we found that galectin-1
bound directly to NiV-F and caused NiV-F to oligomerize,
suggesting that galectin-1 can cross link NiV-F on the surface of
infected cells. Moreover, a single N-glycan site in NiV-F, the F3
glycosylation site, appears to be critical for galectin-1 mediated
inhibition of cell fusion, as mutation of that site to abolish N-glycan
addition, reduced galectin-1 binding to NiV-F and reduced the
inhibitory effect of galectin-1 by 50% [20].
In the present study, we demonstrate that galectin-1 regulates
NiV-F mediated fusion of endothelial cells and neural cells, the
targets of NiV infection in vivo. Since endothelial cell syncytia
formation is a pathognomic feature of NiV infection, we
investigated the mechanisms involved in galectin-1 modulation
of cell-cell fusion. We found that galectin-1 regulates cell fusion at
three distinct points in the process; galectin-1 retains immature
NiV-F0 on the cell surface to reduce production of the mature
NiV-F fusion protein, galectin-1 reduces lateral movement of NiV-
F on the plasma membrane that is required for cell-cell fusion, and
galectin-1 directly inhibits the fusogenic activity of NiV-F by
preventing fusion-peptide exposure and pre-hairpin intermediate
(PHI) formation. The biological significance of our results is
underscored by our demonstration that endogenous galectin-1 on
endothelial cells is sufficient to reduce NiV-F mediated fusion.
These studies identify a unique set of mechanisms for regulating
the pathophysiology of NiV induced syncytia formation at the
target cell level, and contribute to our understanding of the
interaction between galectin-1 and glycoproteins of microbial
pathogens.
Results
Cell surface galectin-1 inhibits syncytia formation in
relevant cell types
We previously found that galectin-1 inhibits syncytia formation
in Vero cells mediated by NiV-F and NiV-G [20]. In vivo,
endothelial cells and neuronal cells are the main targets of Nipah
virus [2], due to the high expression of ephrinB2 and/or ephrinB3
by these cells [6,8]. To explore the role of galectin-1 in NiV-F and
G mediated endothelial and glial cell syncytia formation, we used a
heterologous overlay fusion assay. EphrinB2 and ephrinB3-
negative cells (PK13) were transfected with NiV-F and NiV-G
and plated on a confluent layer of the indicated target cell type
(Fig. 1). Cell-cell fusion could be observed as early as 45 min and
plateaued after approximately 6 hrs. Addition of recombinant
galectin-1 treatment to the co-cultures significantly inhibited
syncytia formation in each of the target cell lines. Vero cells,
human umbilical endothelial cells (HUVECs), and microvascular
endothelial cells (mVECs) all showed a 90% reduction in cell-cell
fusion, and U87 glioblastoma cells showed a 60% reduction in
fusion, compared to control cultures, in the presence of galectin-1
(Fig. 1A). Representative images from the syncytia assays for each
target cell type are shown in Fig. 1B.
Endogenous endothelial galectin-1 inhibits syncytia
formation
Nipah virus infection results in extensive damage to endothelial
cells as a result of syncytia formation, culminating in multi-organ
hemorrhage and death. During viral infection, endothelial cells
become activated and release immune mediators, including
galectin-1 [18,21]. We asked if endogenous endothelial galectin-
1 could affect NiV-F mediated syncytia formation, using the
heterologous fusion assay as in Fig. 1. To activate HUVECs, the
cells were cultured in 20% human serum for four days, a process
that increased cell surface galectin-1 protein expression in these
cells [21]. Galectin-1 expression on the cell surface was quantified
by flow cytometry, and activated HUVECs demonstrated a
consistent increase in cell surface galectin-1 compared to resting
cells (Fig. 2A). Activated HUVECs also showed a significant
decrease (40–50%) in cell-cell fusion, which correlated with the
increase in cell surface galectin-1 (Fig. 2B).
Conversely, in order to determine if endogenous galectin-1,
even on resting HUVECs, was sufficient to affect NiV-F and G
mediated syncytia formation, we reduced expression of galectin-1
in HUVECs using lentiviral vectors expressing siRNAs targeted
against galectin-1. A combination of three siRNAs reduced
galectin-1 protein approximately 70% (data not shown), and
reduced cell surface galectin-1 approximately two-fold (Fig. 2C).
Reduction of endogenous galectin-1 had a dramatic effect on
syncytia formation, as HUVECs treated with siRNA to galectin-1
demonstrated 2.5-fold increase in syncytia formation, compared to
cells treated with control siRNA (Fig. 2D). Infection of HUVECs
with lentiviral vectors containing no siRNA, or siRNA against an
irrelevant protein, had no effect on syncytia formation, which was
identical to that observed in uninfected cells (data not shown).
To confirm that cell surface galectin-1 was responsible for the
effect on syncytia formation, we added exogenous galectin-1 to
HUVECs in which galectin-1 expression was decreased by siRNA.
We observed the expected increase of cell surface galectin-1
(Fig. 2C), as well as a decrease in syncytia formation (Figure 2D).
Thus, endogenous galectin-1 on the surface of endothelial cells
inhibits NiV-F/G mediated syncytia formation, underscoring the
biological relevance of the effect of galectin-1 on NiV mediated
cell-cell fusion.
Author Summary
Nipah virus (NiV) is classified as a ‘‘priority pathogen’’ by
the NIH. NiV infection of humans results in multi-organ
hemorrhage due to endothelial syncytia formation, and
also causes fatal encephalitis in up to 70% of patients. As
there are no effective vaccines or therapeutics for NiV,
understanding the mechanism of endothelial damage by
NiV is a critical goal. Our present work defines the
interaction between galectin-1, an innate immune lectin
that is secreted by human endothelial cells, with the fusion
glycoprotein of NiV. We demonstrate that galectin-1 can
block the function of the NiV-F protein via three distinct
mechanisms, and thus reduce the ability of NiV-F to cause
endothelial cell-cell fusion. Importantly, in this study, we
use human endothelial cells, the primary target of Nipah
virus in vivo, and demonstrate that endogenous galectin-1
made by endothelial cells contributes to limiting cell-cell
fusion caused by NiV-F. As endothelial syncytia formation
is one of the primary pathophysiologic events in Nipah
virus infection, contributing to the hemorrhagic diathesis
seen in infected patients, understanding the mechanism of
endothelial cell fusion and the ability of galectin-1 to
ameliorate cell fusion are critical for development of new
approaches to mitigate these events.
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plasma membrane
Galectin-1 regulates the distribution and residence time of cell
surface glycoproteins by binding to glycan branches on glycopro-
teins to create a cell surface lectin-glycoprotein lattice [22]. Lattice
formation can have a variety of effects, including decreasing lateral
mobility of glycoproteins. Lateral mobility is critical for effective
cell-cell fusion mediated by NiV-F and NiV-G, as it is assumed
that the F and G glycoproteins must physically separate in order to
facilitate cell fusion [13,23]. To determine the effect of galectin-1
on the lateral mobility of NiV-F, we performed fluorescence
recovery after photobleaching (FRAP) analysis, using GFP-tagged
NiV-F [24]. NiV- FGFP was expressed on transfected Vero cells
(Fig. 3A) and mediated cell-cell fusion when co-transfected with
NiV-G (Fig. 3B). Galectin-1 was also efficiently able to inhibit
fusion mediated by NiV-FGFP and NiV-G (Fig. 3C).
To determine the effect of galectin-1 on NiV-F lateral
movement, we measured the fluorescence recovery of NiV-FGFP
(lateral diffusion) in the presence or absence of galectin-1 (Fig. 3D).
We observed 50–60% recovery of NiV-FGFP fluorescence within
20 sec of photobleaching in the absence of galectin-1 (Fig. 3D).
Addition of galectin-1 slowed the initial rate of fluorescence
recovery, and also reduced overall fluorescence recovery to 25%
(Fig. 3D). Thus, the presence of galectin-1 retarded NiV-F lateral
movement on the cell surface.
Galectin-1 prevents endocytosis of NiV-F and inhibits
maturation
The formation of galectin-glycan lattices on the cell surface has
also been shown to reduce the rate of endocytosis of cell surface
glycoproteins [25,26]. As described above, NiV-F is produced as
an immature precursor, NiV-F0, which is expressed on the cell
surface and undergoes endocytosis and proteolytic processing to
produce the fusion competent mature protein NiV-F1/2. We asked
if cell surface galectin-1, in addition to reducing lateral mobility of
NiV-F, altered endocytosis of NiV-F0. Cells expressing NiV-F
were biotinylated to label cell surface proteins and incubated at
37uC to allow for endocytosis in the presence or absence of
galectin-1. Following endocytosis, remaining cell surface biotin
was removed by reduction with glutathione, and internalized
biotinylated NiV-F was quantified in cell lysates. Addition of
galectin-1 decreased the amount of internalized NiV-F by
approximately 50%, compared to control-treated cells (Fig. 4A).
Galectin-1 also decreased the rate of NiV-F internalization by
approximately 50%, (Fig. 4A) over the first 30 min, before
reaching equilibrium.
As galectin-1 inhibited endocytosis of NiV-F from the cell
surface, and NiV-F endocytosis is required for proteolytic
processing [11,27], we investigated the effect of galectin-1 on
proteolytic processing of NiV-F. Cells expressing NiV-F were pulse
labeled and chased in the presence or absence of galectin-1. As
shown in Fig. 4B, galectin-1 treatment decreased the processing of
NiV-F0 into NiV-F1/2. At time 0, there was little to no NiV-F0
cleavage, indicated by the absence of F1 and F2 bands. After four
to six hrs, a fraction of NiV-F0 was cleaved into NiV-F1 and NiV-
F2; however, the presence of galectin-1 significantly reduced
processing of NiV-F0 as evidenced by the decrease in NiV-F1 and
NiV-F2. The amount of cleavage was quantified by comparing the
amount of processed NiV-F (F1+F2) to total NiV-F protein.
Addition of galectin-1 decreased NiV-F processing by approxi-
mately 50% at the 6 hour time point (Fig. 4C), which is
approximately the amount of endocytosis reduction seen in the
presence of galectin-1 (Fig. 4A). Taken together, these results
demonstrate that galectin-1 reduces NiV-F processing by binding
to and decreasing internalization of the NiV-F0 precursor.
Galectin-1 inhibits the function of mature NiV-F1/2 fusion
protein
To further explore the interaction between galectin-1 and NiV-
F, we used a quantitative heterologous fusion assay [13,20], which
combines ephrinB2 positive cells stably expressing the T7
polymerase (BSRT7) and ephrinB2 negative cells (PK-13)
Figure 1. Galectin-1 blocks NiV-F and G mediated syncytia
formation of endothelial and glial cells. A, Quantification of
galectin-1 inhibition. PK-13 (ephrinB2 negative) cells expressing NiV-F
and NiV-G were added to monolayers of ephrinB2 positive cells, Vero
(control), HUVEC, mVEC, and U87. Heterologous fusion in the absence
and presence of 20mM galectin-1 (white and black bars respectively)
were quantified as described in Experimental Procedures. Data are
mean 6 SD of triplicate samples from one of three replicate
experiments. B, Representative images of cell fusion in the absence
or presence of galectin-1. Left panels show multinucleated syncytia in
the indicated cell type. Right panels are cells treated with galectin-1
(206).
doi:10.1371/journal.ppat.1000993.g001
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T7 dependent promoter; in this system, luciferase expression is
dependent on fusion of the two cell types. We used this assay to ask
if galectin-1 inhibition of fusion involved interaction of galectin-1
with mature NiV-F, as well as inhibition of NiV-F0 endocytosis
and maturation, as seen in Fig. 4. We found that, in this assay,
addition of galectin-1 inhibited cell fusion by 80%, and galectin-1
mediated inhibition required the dimeric form of galectin-1, as a
monomeric galectin-1, N-Gal-1, was not effective at blocking cell
fusion, while a covalently linked galectin-1 dimer (GG) was
effective at blocking fusion (Supplmentary Fig. S1A). In addition,
in this assay, galectin-1 mediated inhibition of fusion was specific
and carbohydrate mediated, as the inhibitory effect was abrogated
by addition of lactose, a preferred glycan ligand for galectin-1, but
not by sucrose (Supplementary Fig. S1B).
Chlorpromazine is an endocytosis inhibitor that reduces NiV-F
endocytosis, cleavage, and maturation [27]; cells treated with
chlorpromazine at the time of transfection with NiV-G and NiV-F
demonstrated virtually no maturation of nascent NiV-F0 (Fig. 5A).
We reasoned that, if galectin-1 plus chlorpromazine were added to
cells already expressing mature NiV-F, any effect of galectin-1 on
cell fusion would indicate that galectin-1 bound to and directly
inhibited the fusogenic activity of mature NiV-F, rather than
reducing maturation of NiV-F0. Indeed, we found that addition of
galectin-1 to chlorpromazine treated cells inhibited syncytia
formation above the level of inhibition observed with chlorprom-
azine alone (Fig. 5B), suggesting that galectin-1 can inhibit the
function of the mature fusion protein, in addition to inhibiting
endocytosis of NiV-F0.
To further demonstrate that galectin-1’s inhibitory activity can
be effected through mature NiV-F, we used a real-time fusion
kinetics assay [28] (Fig. 5C). Non-permissive effector cells
(receptor-negative) were co-transfected with beta-lactamase,
NiV-G, and NiV-F and then added to ephrinB2-expressing
293T target cells labeled with CCF2-AM dye. Cell-cell fusion
was detected by analyzing the shift from green to blue
Figure 2. Endogenous endothelial galectin-1 inhibits NiV-F and NiV-G mediated syncytia formation. A, Activated HUVECs have
increased cell surface galectin-1 compared to resting cells. Flow cytometric analysis of cell surface galectin-1 on resting (light grey) and activated
(dark grey) HUVECs, and on resting HUVECs plus exogenous galectin-1 (black) Data are mean 6 SEM of three independent experiments, each done in
triplicate. B, Activated HUVECs are resistant to NiV-F and NiV-G mediated cell fusion. Heterologous cell fusion of resting (light grey) and activated
(dark grey) HUVECs, and resting HUVECs plus exogenous galectin-1 (black). Data are mean 6 SD of triplicate samples from one of three replicate
experiments. C, Reduction of cell surface galectin-1 by siRNA. Flow cytometric analysis of cell surface galectin-1 on resting HUVECs (grey filled), siRNA
treated HUVECs (grey line), and siRNA treated HUVECS with 20mM exogenous galectin-1 (black line). D, Reduction of cell surface galectin-1 in HUVECs
increases susceptibility to NiV-F and G mediated cell fusion. Heterologous cell fusion of resting cells (light grey), cells with reduced galectin-1 (white),
and cells with reduced galectin-1 plus exogenous galectin-1 (dark grey). Data are mean 6 SD of triplicate samples from one of three replicate
experiments.
doi:10.1371/journal.ppat.1000993.g002
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cleavage of CCF2-AM. In the absence of galectin-1, cell-cell fusion
plateaued at about 100 min after mixing of the cells, while
addition of galectin-1 completely inhibited fusion in this assay. As
we start to observe an effect of galectin-1 on cell fusion within
25 min, galectin-1 is likely affecting mature fusion protein already
on the effector cell surface, rather than solely affecting maturation
of nascent NiV-F0.Thus, the ability of galectin-1 to inhibit fusion
in this assay further supports a direct interaction between galectin-
1 and the mature NiV-F fusion protein.
To more specifically understand the effect of galectin-1 binding
to mature NiV-F on the fusion process, we examined triggering of
NiV-F in the presence and absence of galectin-1. Current models
of Nipah virus membrane fusion suggest that NiV-G binding to
the cell surface receptor ephrinB2 triggers a conformational
change in NiV-F; this triggering results in exposure of the fusion
peptide in the pre-hairpin intermediate (PHI). The PHI then
undergoes six-helix bundle formation, which is the conformational
change that physically drives fusion of opposing membranes [29].
In NiV-F, the two heptad repeat regions, HR1 and HR2, fold next
to each other during six-helix bundle formation. The HR1 region
is transiently exposed during PHI formation, but before six-helix
bundle formation. We have previously demonstrated [23] that a
biotinylated peptide corresponding to the HR2 region can inhibit
NiV-F mediated fusion by binding to the exposed HR1 region
during PHI formation; HR2 peptide binding serves as a functional
assay for formation of the PHI or NiV-F triggering. As Figs. 5B
and 5C indicated that galectin-1 can block the fusogenic activity of
mature NiV-F, we asked if galectin-1 binding to mature NiV-F
could inhibit the conformational change in NiV-F (triggering or
PHI formation) necessary to expose the fusion peptide, thereby
inhibiting membrane fusion and syncytia formation.
To detect triggering, wild type CHO cells or CHO cells stably
expressing ephrinB2 (CHOB2) were mixed with CHO cells
Figure 3. Galectin-1 interferes with lateral movement of NiV-F on the plasma membrane. A, NiV-FGFP expression on the surface of two
individual Vero cells. B, NiV-FGFP promotes cell fusion when transfected into Vero cells with NiV-G. (206) C, Galectin-1 inhibits fusion mediated by NiV-
FGFP. Fusion of Vero cells in the absence (2) or presence (+)o f2 0 mM galectin-1 was measured as in Fig. 1. D, Galectin-1 inhibited fluorescence
recovery after photobleaching. NiV-FGFP transfected Vero cells were treated with buffer control (black line with black squares) or 20mM galectin-1
(grey line with black triangles), and a portion of the membrane was bleached and measured for fluorescent recovery (y-axis) as a function of time in
seconds (x-axis). Data are mean 6 SD of six replicate measurements from one of two independent experiments.
doi:10.1371/journal.ppat.1000993.g003
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to ephrinB2 is an energy independent process. The biotinylated
HR2 peptide was added to the cells in the presence or absence of
galectin-1, and fusion was induced by incubation at 37uC for an
additional 1.5 hours, because PHI formation is an energy
dependent process. Binding of the HR2 peptide indicates that
triggering has occurred. We observed no triggering of NiV-F at
4uC, regardless of the presence of galectin-1 (Fig. 5D). In the
absence of galectin-1, incubation of the cell mixture at 37uC
resulted in NiV-F triggering as seen by an increase in HR2 peptide
binding. However, addition of galectin-1 reduced HR2 peptide
binding, demonstrating that galectin-1 inhibited triggering of
mature NiV-F (Fig. 5D). The change in HR2 peptide binding in
the presence of galectin-1 is quantified in Fig. 5E. These results
clearly show that galectin-1 can directly inhibit NiV-F triggering,
so that this effect, in addition to inhibition of NiV-F lateral
movement on the cell surface and inhibition of NiV-F0
maturation, contributes to the mechanism of galectin-1 mediated
inhibition of NiV-F mediated cell fusion.
Site-specific glycosylation on NiV-F
The NiV-F fusion protein contains 5 consensus sites for N-
glycosylation, labeled F1–F5; four of these predicted sites have
been found to be glycosylated in vivo (F2–F5) [13]. To establish the
types of N-glycans expressed by NiV-F0 and NiV-F1, glycomic
screening was performed using MALDI-TOF mass spectrometry.
The N-glycans were released by PNGase F and analyzed as their
permethylated derivatives. The resulting spectra exhibit a series of
singly charged sodiated molecular ions ([M+Na]
+) to which
putative structures are assigned based on the molecular compo-
sitions and knowledge of the N-glycan biosynthetic pathway. The
profile for the complete propeptide, NiV-F0, can be seen in Fig. 6A.
The assigned structures on NiV-F0 include high mannose (m/z
1988, 2192, 2396; Man7–9GlcNAc2), complex (m/z 2040–3416;
Fuc0–1NeuAc0–2Hex0–7HexNAc4–6) and hybrid structures (m/z
1550, 1999; Fuc1Hex4–5HexNAc2–3). The complex and hybrid
structures contain lactosamine (Gal-GlcNAc) moieties that can be
recognized by galectin-1. The MALDI-TOF mass spectrum of
permethylated N-glycans from NiV-F1 is displayed in Supplemen-
tary Figure S2. Comparison of the structures released from NiV-F0
and NiV-F1 suggests that the glycosylation sites on the NiV-F2
subunit (F2 and F3 glycans) are modified with larger complex
structures than those on NiV-F1 subunit (F4 and F5 glycans).
Previous research has shown that galectin-1 preferentially binds
to the F3 glycan and this contributes significantly to galectin-1
inhibition of NiV-F mediated fusion of Vero cells. The other NiV-
F N-glycans can also contribute to galectin-1 binding, as shown by
co-immunoprecipitation studies with the NiV-F3 mutant [20]. In
order to confirm the differences in site glycosylation suggested in
the comparative MS data, and, where possible, deduce which
subtypes of N-glycan occur at each glycosylation site, we
performed online nano-LC ES-MS and data-dependent MS/MS
analyses on tryptic peptides and glycopeptides from purified NiV-
F samples. A peptide containing the F3 glycosylation site
(GALEIYKNNTHDLVGDVR) was observed at an elution time
of ,50 min (Figure 6B, top panel). Carbohydrate structures were
assigned by identifying neighboring ions separated by mass
Figure 4. Galectin-1 inhibits NiV-F0 endocytosis and matura-
tion. A, Galectin-1 decreases internalization of NiV-F0 from the plasma
membrane. Cells transfected with NiV-F were cell surface biotinylated,
then incubated in the presence of 20mM galectin-1 (bold line), or buffer
control (dashed line), for the indicated times to allow internalization.
Internalized biotinylated NiV-F was quantified by ELISA. Percent
internalization was determined as the amount of internalized biotiny-
lated NiV-F compared to total biotinylated NiV-F at the initial timepoint.
Data are mean 6 SEM for seven replicate experiments. B, Galectin-1
inhibits NiV-F0 proteolytic processing. 293T cells expressing NiV-F were
pulse-labeled with
35S-methionine, then chased for 4 or 6 hrs in the
presence or absence of galectin-1. NiV-F was immunoprecipitated with
anti-NiV-F polyclonal sera and proteolytic processing analyzed by
immunoblotting. C, Graphic representation of data in B. Cleavage ratio
was determined as the amount of processed NiV-F (F1+F2) compared to
total NiV-F protein. Data are mean 6 SEM of three replicate
experiments.
doi:10.1371/journal.ppat.1000993.g004
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of 26 different glycan compositions were assigned. The carbohy-
drate structures are mostly complex and hybrid-type structures.
The most intense peak assigned in Figure 6B (top panel)
corresponds to a mono-sialylated, core-fucosylated bianntennary
carbohydrate structure (m/z 1019.38
4+). Previous research has
shown that alpha 2,6-linked sialic acid caps block galectin-1
binding while alpha 2,3 sialic acid caps do not (Stowell et al. 2008).
Treatment of the tryptic glycopeptides prior to the nano-LC ES-
MS experiment with Sialidase S (a sialidase that specifically cleaves
the alpha 2,3 linked sialic acid) revealed that both alpha 2,3 and
alpha 2,6-linked sialic acid are present, with 2,3-linked sialic acid
being the more abundant (Fig. 6B, lower panel). These results
suggest that the F3 glycan contains abundant putative binding sites
for galectin-1. Analysis of the other glycosylation sites revealed that
the F5 site carries only high mannose-type glycans (Supplementary
Figure 5. Galectin-1 inhibits function of mature NiV-F. A, Chlorpromazine inhibits maturation of NiV-F0. PK-13 were transfected with NiV-F in
the absence or presence of chlorpromazine (50mM). Cells were incubated overnight and NiV-F0 and NiV-F1 detected by immunoblotting. B, Galectin-1
inhibits heterologous cell fusion in the presence of chlorpromazine. BSRT7 ephrinB2 positive cells were added to a monolayer of PK13 cells
transfected with NiV-F, NiV-G and a luciferase construct with a T7 dependent promoter in the presence or absence of chlorpromazine (50mM) and
galectin-1 (20mM). * p=0.0002, calculated using Student’s t test. C, Fusion kinetics in the presence or absence of galectin-1. NiV-G and NiV-F were
expressed in effector PK13 cells, and the relative rate of fusion assessed on target 293T cells loaded with CCF2 dye. Relative fusion is the ratio of blue
to green fluorescence from NiV-G and NiV-F-transfected effector cells minus the ratio of background blue to green fluorescence from empty-vector
(pcDNA3)-transfected cells. Each data point is the mean of three independent experiments. D, Galectin-1 inhibits the ability of NiV-F to be triggered
for membrane fusion. CHO cells expressing NiV-F and NiV-G were mixed with CHO cells (negative control, grey shaded) or CHOB2 cells (ephrinB2
positive, black line) for 1.5 hr at 4uC. Cell mixtures were brought to 37uC or kept at 4uC for 1.5 hr with 1 mM biotinylated HR2 peptide, in the presence
or absence of galectin-1GG; top, 4uC without and with galectin-1; bottom, 37uC without and with galectin-1. E, Inhibition of F triggering at 37uC; data
are mean fluorescence intensity of triplicate determinations 6 SEM. See also Supplementary Figure S1.
doi:10.1371/journal.ppat.1000993.g005
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substantially to galectin-1 binding. The F4 site carries mostly
complex-type structures, and the major peak at F4 is the sialylated
biantennary glycan without core fucose (Supplementary Fig. S4),
indicating that the F4 glycan may contribute to galectin-1 binding.
Galectin-1 inhibits NiV-F maturation and fusion through
binding to the F3 glycan
We previously found that only the F3 glycan on NiV-F, but not
the other N-glycans, is critical for optimal galectin-1 binding and
inhibition of fusion of Vero cells [20]. Thus, we asked if the F3
glycan was also important for galectin-1 inhibition of fusion of
endothelial cells and glial cells, the target cells of NiV. PK13 cells
transfected with NiV-G and NiV-F or NiV-F3, lacking the F3
glycan, were added to HUVECs and U87 cells, and syncytia
formation was scored in the presence or absence of galectin-1
(Fig. 7A). There was reduced inhibition of fusion by galectin-1
between PK13 cells expressing NiV-F3 and target cells, compared
to cells expressing wildtype NiV-F3. These results indicate that
galectin-1 partially inhibits fusion in relevant cell types by binding
to the F3 glycan on NiV-F.
We also asked if the F3 glycan on NiV-F0 is critical for galectin-
1 inhibition of endocytosis and maturation, as seen in Fig. 4A. The
reduced endocytosis of NiV-F0 in the presence of galectin-1 was
essentially abrogated in cells expressing the NiV-F3 mutant
(Fig. 7B); in addition, we quantified processed NiV-F and NiV-
F3, and found that, as we saw in Fig. 4B, processing of wildtype
NiV-F was reduced approximately 50% in the presence of
galectin-1, while there was ,20% reduction of NiV-F3 processing
in the presence of galectin-1 (data not shown). Taken together
these data indicate that the F3 glycan on NiV-F is critical for
galectin-1 inhibition of endocytosis of immature NiV-F0.
Discussion
The galectins, a family of mammalian carbohydrate binding
proteins, interact with a broad range of mammalian cell surface
glycoproteins to regulate essential functions in virtually every type
of cell, including neural, immune and endothelial cells. Recent
reports have shown that galectins can also directly bind
glycoproteins on microbial pathogens, including viruses, bacteria
and fungi, and that some galectins can participate as innate
immune effectors. For example, galectin-3 binding to Candida
albicans is fungicidal [30] and galectin-4 and galectin-8 binding to
Escherichia coli is bacteriocidal [31]. Conversely, some pathogens
exploit endogenous galectins to promote infection or evade host
immune responses [32,33,34,35,36,37,38,39]. Enveloped viruses
use glycoproteins as both fusion and attachment molecules, and
galectins have been shown to interact with envelope glycoproteins
on HIV, HTLV and NiV [20,33,35,37,40]. Previous work from
our laboratories demonstrated that both NiV-G and NiV-F
Figure 6. The F3 N-glycan on NiV-F is a complex N-glycan containing putative binding sites for galectin-1. A, MALDI-TOF mass
spectrum of all permethylated N-glycans from NiV-F0. Annotated structures were deduced by taking into account theoretical compositions and
knowledge of the biosynthetic pathways (for further information, refer to http://www.ncbi.nlm.nih.gov/books/bv.fcgi?rid=glyco.TOC&depth=2). All
molecular ions are [M+Na]
+. Peaks labeled with * represent contaminating hexose polymers. Unlabelled peaks are non-carbohydrate contaminants or
permethylation products. B, Glycan component of the F3 glycopeptide, GALEIYKNNTHDLVGDVR, and effect of sialidase S digestion. Top panel – NiV-
F0 was digested with trypsin and the peptide/glycopeptide mixture was analysed by LC-ES-MS/MS; the summed MS data for the F3 glycopeptide are
shown. Bottom panel – The LC-ES-MS/MS experiment was repeated after treatment of the tryptic digest of NiV-F0 with Sialidase S; summed MS data
for the partially desialylated F3 glycopeptide are shown. Unannotated peaks correspond to peptides. Molecular ions attributable to glycopeptides are
annotated with m/z values and subscripted charge states. Peaks labeled in bold correspond to molecular ions that have shifted on Sialidase S
digestion; these peaks are also assigned a potential glycan structure. Symbol nomenclature is that used by the Consortium of Functional Glycomics
(CFG) (see key below). See also Figure S2. Key: Galactose (yellow circle), Mannose (green circle), GlcNAc (blue square), Fucose (red triangle), NeuAc,
(purple diamond).
doi:10.1371/journal.ppat.1000993.g006
Figure 7. The F3 glycan is critical for galectin-1 inhibition of
NiV-F maturation and function. A, The F3 mutant (NiV-F missing
the F3 glycan) is resistant to galectin-1 inhibition of syncytia formation
in endothelial and glial cells, using the heterologous cell fusion assay
described in Fig. 1. PK13 cells expressing NiV-G and either wildtype NiV-
F (white) or NiV-F lacking the F3 glycan (black) were added to indicated
cells in the presence of galectin-1 (HUVEC, 10mM; U87, 20mM). The y-axis
shows percent inhibition of fusion. Data are mean 6 SD of triplicate
samples from one of three replicate experiments. * p=0.0001,
calculated using unpaired Student’s t test. B, The F3 glycan on NiV-F
is critical for galectin-1 inhibition of NiV-F0 internalization. Cells
transfected with NiV-F3 (lacking the F3 glycan) were cell surface
biotinylated and incubated in the presence of galectin-1 (20mM) (bold
line), or buffer control (dashed line), for the indicated times to allow
internalization. Internalized NiV-F3 was quantified as in Fig. 4. Data are
mean 6 SEM for seven replicate experiments.
doi:10.1371/journal.ppat.1000993.g007
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reduced syncytia formation triggered by NiV-F; galectin-1
inhibition of syncytia formation was specific for paramyxoviruses,
as we did not observe inhibition of cell fusion induced by HTLV-2,
vaccinia and MLV [20]. As inflammation and viral infection can
stimulate production of galectins by endothelial cells [15,16,18],
endogenous galectin-1 may contribute to host defense against NiV
infection by mitigating the endothelial cell syncytia formation that
is a hallmark of Nipah infection, as we have clearly demonstrated
that endogenous galectin-1 can attenuate endothelial cell fusion in
vitro (Fig. 2). While autopsy studies of patients who succumbed to
NiV infection found endothelial cell syncytia in numerous organs
including brain [2,3], variation in galectin-1 expression among
infected individuals may contribute to susceptibility or resistance
to viral-induced pathophysiology and, in part, explain why some
infected individuals do not progress to encephalitis.
We investigated the effect of galectin-1 at each stage of the cell
fusion process, and have identified three points at which galectin-1
inhibits NiV-F mediated syncytia formation. First, galectin-1 reduced
lateral mobility of NiV-F on the plasma membrane (Fig. 3). Second,
galectin-1 retarded endocytosisand maturation of the precursorNiV-
F0 (Fig. 4). Third, galectin-1 prevented the triggering of mature NiV-
F into the fusion-competent form (Fig. 5). Lateral mobility in the
plasma membrane is important for NiV-F mediated cell fusion, as the
physical separation of NiV-F and NiV-G is required for the
conformational change in NiV-F necessary for membrane fusion
[23,28]. Galectin-1 inhibition of the lateral movement of NiV-F could
contribute to reduced ability of mature NiV-F to form the fusion
competent PHI on the cell surface, in addition to the direct inhibition
of PHI formation that we observed in Fig. 5.
All these effects are congruent with data from prior studies
demonstrating that galectin interacts with endogenous mammalian
plasma membrane glycoproteins to form galectin-glycoprotein
lattices on the cell surface [22,41]. Formation of these lattices
increases the local concentration of galectins at the cell surface,
and also has direct effects on the glycoproteins in the lattice, as
galectin-glycoprotein lattices can regulate the distribution, resi-
dence time, and function of glycoproteins on the plasma
membrane [24,25,42,43,44,45]. Galectin-glycoprotein lattice for-
mation has been shown to inhibit lateral diffusion of EGF
receptors on tumor cells [24]. Galectin-glycoprotein lattices also
reduce endocytosis of EGF receptors on tumor cells, Glut-2
receptors on pancreatic cells, and receptor tyrosine phosphatase
beta on neural cells [24,25,26]. The present study provides the first
demonstration that galectin-1 on the cell surface reduces lateral
mobility and endocytosis of a viral glycoprotein, rather than an
endogenous mammalian glycoprotein. Lattice formation between
galectin-1 and NiV-F likely contributes to inhibition of NiV-F
maturation, reduced mobility, and reduced triggering that we
observed.
Our findings also emphasize the specificity of the interaction
between galectin-1 and unique glycans on a viral envelope
glycoprotein. Glycoproteomic analysis showed that the most
abundant glycan at the F3 site is a monosialylated biantennary
glycan with a 2–3 linked sialic acid (Fig. 6). This structure fulfils
the known requirement for a galectin-1 ligand [46]. Fig. 7, as well
as our previous report, shows that the F3 glycan on NiV-F
participates in galectin-1 inhibition of syncytia formation at two
distinct points; the F3 glycan appears essential for galectin-1
inhibiting maturation of NiV-F0 and also substantially contributes
to the galectin-1 effect on the function of mature NiV-F. This level
of specificity for a particular glycan on a glycoprotein counter-
receptor is quite novel, in that previous reports on mammalian
lectins interacting with viral glycoproteins emphasized simple
pattern matching or binding to dense and repetitive arrays of
terminal monosaccharide ligands [47,48,49]. In contrast, a
significant component of the interaction between galectin-1 and
NiV-F primarily involves a single glycosylation site on the viral
glycoprotein. This interaction emphasizes the site-specific nature
of glycan addition and subsequent modification during viral
glycoprotein maturation and transport to the cell surface. As
shown in Fig. 6, there is significant heterogeneity among the
different glycans attached to NiV-F. Similar microheterogeneity
has been observed for the glycans attached to HIV gp120 [50].
This microheterogeneity would substantially contribute to selective
interaction of viral glycoproteins with endogenous mammalian
lectins, such as C-type lectins and galectins, or with antibodies that
recognize specific glycans on viral glycoproteins. Interestingly, F3
glycan removal resulted in the highest levels of hyperfusiogenicity
compared to the removal of other glycans on NiV-F [13]. This is
consistent with F3 glycan removal reducing the inhibitory effects of
endogenous galectin-1.
This report defines several molecular mechanisms by which
galectin-1 binding to NiV-F interferes with maturation and
function of NiV-F to reduce cell fusion, and also demonstrates
that endogenous endothelial galectin-1 can influence the extent of
syncytia formation. Since syncytia formation is the pathognomonic
hallmark of NiV infection, we predict that, in vivo, galectin-1 may
reduce pathophysiologic consequences during the course of an
infection. An 11kb region containing the gene coding for galectin-
1 contains 14 different single nucleotide polymorphisms (SNP)
[51], and this genetic variability may partially account for the
range of pathophysiological consequences seen in Nipah virus
infection, as SNPs in other galectins have been found to be
associated with increased disease risk [52]. Our studies focus on
cell-cell fusion, as syncytia formation is the event that primarily
contributes to the endothelial destruction and hemorrhagic
sequelae in NiV infection. However, galectins may also influence
attachment of viruses to target cells [33,35,37,40], although
galectin mediated cell attachment is fundamentally distinct from
the specific fusion inhibitory mechanisms that we have elucidated
in this study. Galectins can play multiple distinct roles in complex
biologic processes such as pathogen entry, replication and
dissemination, so that our goal is to define all the roles played
by galectin-1 during the entire course of Nipah virus infection of
human host cells.
Materials and Methods
Cell lines and reagents
Vero cells and CHO cells (ATCC) were maintained in MEM
alpha (Invitrogen) with 10% FBS (Hyclone) and 2mM Glutamax
in 5%CO2 at 37uC. PK-13 porcine fibroblast cells and 293T cells
were maintained in DMEM (Invitrogen) with 10% FBS (Hyclone)
and 2mM Glutamax. BSR cells stably transfected with T7
polymerase were maintained in DMEM with 10% FBS (Hyclone),
2mM Glutamax, and 0.5mg/ml G418 (Sigma). U87 glioblastoma
cells (gift of P. Mischel, UCLA) were maintained in DMEM with
10% FBS (heat inactivated at 55uC for 30 min), 2mM Glutamax,
and 50 units/ml penicillin/streptomycin. mVECs [6] and
HUVECs (BD Biosciences) were maintained in MDCB-131
Complete media with fetal bovine serum and antibiotics (VEC
Technologies, INC.).
Codon-optimized NiV-F and G plasmids tagged with AU1 were
previously described [20]. NiV-F3 plasmid (encoding NIV-F
lacking the F3 glycan) was previously described [13]. NiV-F-
GFP plasmid was created by synthesizing a fusion gene between
NiV-F and GFP using overlapping PCR. Oligonucleotide
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optimized NiV-F and 39region of GFP. An additional oligonucle-
otide that overlaps the 39 region of NiV-F and the 59 region of
GFP was also designed which did not contain the stop codon at the
end of the NiV-F ORF and included a GGG linker between the
two genes. NiV-F (1.6 kb) and GFP (0.8kb) genes were amplified
by PCR using the appropriate 59 or 39 oligonucleotide primers and
the overlapping primer. The two PCR products were gel purified
and used together as template for another PCR reaction using the
original 59 and 39 primers. The resulting 2.2kb fusion gene
product was subcloned into pcDNA3 (Invitrogen) and sequence
verified. Recombinant human galectin-1 was expressed in E. coli
and purified by affinity chromatography on lactosyl-Sepharose, as
in [53]; in all assays, the buffer control includes 8mM dithiothreitol
(DTT), as galectin-1 is prepared and stored in PBS with DTT.
Heterologous fusion assay
PK-13 cells were transfected with codon-optimized, AU1-
tagged NiV-F, NiV-F3, or NiV-FGFP and HA-tagged NiV-G at
15ug per plasmid using Lipofectamine 2000 (Invitrogen). Cells
were cultured overnight, lifted with 5mM EDTA (ethylenedi-
aminetetraacetic acid) and overlayed in the absence or presence of
galectin-1 onto ephrinB2 positive cells (Vero, U87, mVEC, or
HUVEC). After 2 hrs (Vero/U87) or 6 hrs (HUVEC/mVEC),
cells were fixed with 2% paraformaldehyde (EMS). After 49,69-
diamidino-2-phenylindole (DAPI) staining (Invitrogen), nuclei
inside syncytia per 6100 field were counted by fluorescence
microscopy as previously described [20].
Cell surface staining for galectin-1
HUVEC cells were incubated with or without 20mM galectin-1
for 30 min at 37uC. Cells were fixed in DTSSP (Thermo
Scientific) at 0.2mg/ml for 10 min at room temperature, and
quenched by addition of 100ml of 1M Tris pH 7.5 for 15 min at
room temperature. Cells were washed with PBS and lifted with
5mM EDTA at 37uC for 10 min. Cells were stained with a rabbit
galectin-1 antibody (Strategic) for 1 hr at 4uC. Cells were washed
with PBS and stained with FITC-conjugated AffiniPure goat anti-
rabbit IgG (H+L) antibody (Jackson ImmunoResearch) at 8mg/ml
for 1 hour at 4uC. Cells were washed in PBS and resuspended in
PBS with 1% BSA (Gemini BioProducts) for analysis by flow
cytometry. Flow cytometric analysis of HUVEC cell surface
galectin-1 was performed on a Becton-Dickinson FACScan, using
CellQuest software (Becton-Dickinson).
Galectin-1 knockdown
3 different siRNA constructs directed toward human galectin-1
mRNA in lentivectors (pSIH1-H1-copGFP plasmid) (System
Biosciences) were packaged into VSV using pPACKH1 Lentivector
Packaging Kit (System Bioscience).Lentiviruswasproducedin293T
cells; three different viruses corresponding to the 3 different siRNAs
were isolated, as well as a virus containing only the GFP infection
marker, and a virus containing siRNA to an irrelevant protein,
CD43. HUVECs were plated at 1.4610
5 cells per well in a 6 well
tissue culture dish (Corning). A single well of HUVECs was treated
with each virus (MOI of 3.3, total MOI of 10) in PBS with 1% heat
inactivated FBS (Hyclone) and cells were spinoculated at 2000 rpm
at 37uC for 2 hrs. Infected cells were grown in full media for 4 days
and knockdown was assessed by western blot and flow cytometry.
FRAP
Fluorescence Recovery After Photobleaching analysis of Vero
cells transfected with NiV-FGFP plasmid was performed in 35mm
glass bottom culture dishes (MatTek) on a 37uC heated stage. Cells
were treated with 20mM galectin-1 or buffer control for 10 min
prior to photobleaching. Images were acquired on a confocal
microscope (Leica SP2 1P-FCS) with a HCX PL APO 63.061.40
oil objective and fully opened pinhole. Photobleaching of NiV-F-
GFP was performed using 5 scans with the 488-nm laser at full
power. Recovery data (six cells per time point from each of two
independent experiments) was collected every 2.2 seconds for a
total of 25 time points. Images were acquired with equivalent
acquisition settings including pre-bleach, bleach, and post-bleach
measurements. Bleaching and recovery were measured in a fixed
area and compared to an area absent of fluorescence outside of the
cell.
NiV-F endocytosis assay
PK-13 cells were transfected with NiV-F or NiV-F3. After
overnight incubation, cells were washed twice with KRPH buffer
(128mM NaCl, 4.7mM KCl, 1.25mM CaCl2, 1.25mM MgSO4,
5mM Na2HPO4, 20mM Hepes pH 7.4) and cell surface
biotinylated using the EZ-Link sulfo-NHS-SS-Biotin (Pierce).
Biotinylation was quenched in 20mM glycine and cells were
washed again in KRPH buffer. Cells were incubated in media with
or without galectin-1 or buffer control for the designated times at
37uC to allow endocytosis. After timepoints, cells were washed and
remaining biotin cleaved twice with cleavage buffer (90mM NaCl,
1.25mM CaCl2, 1.25mM MgSO4, 2mg/ml BSA, 50mM gluta-
thione pH 8.6) and quenched in 20mM glycine for 15 min. Cells
were lysed in lysis buffer (20mM Tris-HCL pH 7.5, 100mM
NH2SO4, 0.1% BSA, 0.75% Trition X-100, 0.01% NaN3).
Biotinylated NiV-F in cell lysates was quantified by ELISA using
mouse anti-AU1 (1:1000) coated Reacti-Bind goat anti-mouse
plates (Pierce) to capture AU1-tagged NiV-F, and detected with
streptavidin-HRP (Biorad).
Metabolic labeling and pulse chase
293T cells grown in 6-well plates were transfected with 0.25mg
of NiV-F plasmid DNA and 1.75mg pcDNA3 per well. 24 hrs post
transfection, cells were incubated in media lacking methionine and
cysteine for 45 min followed by labeling with media containing
35S-cysteine and
35S-methionine (100mCi/ml) for 30 min, and
then in chase (non-radioactive) media for 4 to 6 hrs, in the
presence or absence of 20mM galectin-1. Cells were lysed in 200ml
RIPA buffer (20mM Tris-HCl pH 7.4, 137mM NaCl, 0.1% SDS,
0.5% deoxycholate, 1% NP-40, 2mM EDTA). NiV-F was
immunoprecipitated from cleared cell lysates using a combination
of anti-NiV-F polysera [13] and anti-AU1 antibody each at 1:100
dilution, and Protein G agarose (Pierce). Precipitates were washed
twice in RIPA buffer and twice with RIPA buffer plus 0.5M NaCl.
Samples were separated on a 14% polyacrylamide gel and data
were quantified and analyzed using a phosphoimager (Molecular
Dynamics 445SI) and ImageQuant (v5.2).
Fusion reporter assay
Fusion-nonpermissive PK-13 target cells were transfected with
codon optimized NiV-F, NiV-G, and a plasmid containing a T7
promoter driven luciferase at a 3:3:1 ratio with 30mg of total
plasmid DNA and grown overnight. BSR cells stably transfected
with a T7 polymerase (BSRT7) were lifted with 5mM EDTA at
37uC for 10 min. BSRT7 cells were co-cultured with transfected
PK-13 cells for 6 hrs with or without galectin-1. After 6 hrs, the
cells were lysed in 0.3% Triton-X 100 by two rounds of freeze/
thaw at 280uC. Luciferase expression was quantified using a
Luciferase assay system (Promega). Briefly, lysates were transferred
to a 96 well opaque black plate, luciferase assay substrate was
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(Turner Biosystems).
Chlorpromazine treatment
PK-13 cells were transfected with NiV-F and simultaneously
treated with chlorpromazine (Sigma) for 16 hrs. Cells were lysed in
50mM Tris-HCl (pH 7.4), 1% Nonidet P-40, 5mM EDTA,
150mM NaCl, 1mM PMSF, 10mg/ml aprotinin, 10mg/ml
leupeptin, and 10mM sodium orthovanadate with scraping.
Lysates were microfuged for 15 min at 10,000 rpm. Samples
were denatured in NuPAGE reducing agent and NuPAGE
Sample Buffer (Invitrogen) before loading. Lysates (10 mg) were
separated on a 12% Bis-Tris gel (Invitrogen NuPAGE Electro-
phoresis System) and electroblotted onto nitrocellulose (What-
man). The membrane was blocked and probed as previously
described [53] using an AU1 antibody (Covance) and NiV-F
proteins were visualized by ECL.
Triggering of NiV-F by NiV-G in the presence or absence
of galectin-1
NiV-F triggering was measured essentially as in [23] except in
the presence or absence of 0.4 mM galectin-1GG [54]. Briefly,
CHO cells were transfected with NIV-F and NiV-G expression
plasmids, plus GFP expression plasmid, at a 13:6:1 ratio,
respectively. 18 hrs post-transfection, a 1:1 ratio of transfected
cells and either CHO (negative control) or CHOB2 (CHO cells
transfected with ephrinB2 [23]) cells were mixed and incubated for
2h ra t4 uC, followed by a 90 min incubation at either 4uCo r
37uC in the presence of excess biotinylated HR2 peptide and in
the presence or absence of 0.4 mM galectin-1GG, as indicated.
Cells were washed with wash buffer (1% FBS in PBS), fixed in
0.5% paraformaldehyde in wash buffer, and washed twice with
wash buffer. Biotinylated HR2 peptide bound to F was detected
using streptavidin-APC (ebioscience). GFP-positive cells were
gated and analyzed for HR2-biotin binding.
Fusion kinetics in the presence or absence of galectin-1
Fusion kinetics were determined in a beta-lactamase reporter
cell-cell fusion assay, as previously described [13,28,55,56], using a
catalytically enhanced and codon optimized beta-lactamase gene
[57,58]. Fusion-nonpermissive PK13 effector cells were co-
transfected with beta-lactamase, NiV-G, and NiV-F expression
plasmids, and mixed with 293T target cells labeled with CCF2-
AM dye for 30 min at 4uC. Galectin-1GG (0.4 mM) or buffer
control was added and the cells moved immediately to 37uC. Cell-
cell fusion was detected by analyzing the shift from green to blue
fluorescence, indicating beta-lactamase cleavage of CCF2-AM.
Fluorescence was quantified every 3 min with a Synergy 2 Multi-
mode microplate reader (BioTek Instruments, Winooski, VT).
Results are expressed as the ratio of blue to green fluorescence
obtained with NiV-G- and NiV-F-transfected effectors minus the
background blue to green fluorescence ratios obtained with NiV-
G- and empty-vector-transfected cells.
Preparation of NiV-F sample for mass spectrometric
analysis
Glycan analysis was performed on NiV-F protein pseudotyped
onto VSV viral-like particles produced in 293T cells. Gel bands
containing purified NiV-F0 and NiV-F1 were destained using
100% acetonitrile, incubated with 10mM DTT for 30 min at
56uC, followed by 55 mM iodoacetic acid for 30 min at RT.
Reduced and carboxymethylated NiV-F was digested with 0.5mg
sequencing grade-modified trypsin (Promega, UK) at 37uC for
14 hrs. Tryptic peptides and glycopeptides were extracted from
the gel pieces by incubating with 0.1% trifluoroacetic acid (TFA)
and 100% acetonitrile; the supernatant was pooled and reduced in
volume on a rotary evaporator. For glycomic screening the
supernatant was lyophilised before being dissolved in 200ml
ammonium bicarbonate (50mM, pH 8.4) and incubated with 5U
of Peptide-N-glycosidase F (PNGase F) (Roche Applied Science,
UK) for 24 hrs at 37uC to release the N-glycans. The reaction was
terminated by lyophilisation. Glycans were separated from
peptides by C18 Sep-Pak purification and permethylated as
previously described [59].
MALDI-TOF and online nano-LC-ES-MS/MS analysis
MALDI-TOF MS and MS/MS data on permethylated N-
glycan samples were acquired in positive ion mode [M+Na]
+ using
a 4800 MALDI-TOF/TOF (Applied Biosystems, UK) mass
spectrometer as previously described [60]. The MALDI data
were processed using Data Explorer 4.9 Software (Applied
Biosystems, UK). Tryptic digests were analysed by nano-LC-ES-
MS/MS using a reverse-phase nano-HPLC system (Dionex (UK)
Ltd, Camberley) connected to a quadrupole TOF mass spectrom-
eter (API Q-STAR Pulsar I, Applied Biosystems, UK) as
previously described [61]. Analysis of the ES-MS and MS/MS
data was aided by use of the Peptoonist algorithm [62].
Sialidase S digestion of NiV-F glycopeptides
Sample was dried, resuspended in 50ml of 50mM ammonium
acetate (pH 5.5) and incubated with 10mU of Sialidase S at 37uC
for 14 hrs. After digestion, NiV-F peptides and desialylated
glycopeptides were desalted and separated using a C18-microtrap
peptide cartridge (Presearch, Basingstoke). The sample was loaded
directly onto the microtrap cartridge with a 25ml gastight syringe.
The microtrap was first solvated with methanol, washed off with
acetonitrile and conditioned with 0.1% TFA. The sample was
loaded onto the column and washed with 0.1% TFA prior to
eluting with 15ml 30 and 60% acetonitrile in 0.1% TFA,
respectively. Eluted fractions were combined and dried down
gently under nitrogen before online LC-ES-MS and MS/MS
analysis.
Supporting Information
Figure S1 Heterologous fusion is inhibited by galectin-1.
Galectin-1 inhibits function of the mature fusion protein. A,
Galectin-1 inhibits heterologous fusion in a dimer dependent
manner. EphrinB2 positive cells stably expressing the T7
polymerase were added to a monolayer of ephrinB2 negative
cells transfected with NiV-F, NiV-G and a luciferase construct
with a T7 dependent promoter. Luciferase expression correlates
with cell fusion. Data are shown as percent fusion based on the
total fusion without any treatment (Lane 2). Lane 1 is a negative
control and lane 3 is heterologous fusion with buffer alone. Lane 4,
30mM galectin-1. Lane 5, 10mM forced galectin-1 dimer (GG).
Lane 6, 30mM monomeric galectin-1 mutant, N-Gal-1. B,
Galectin inhibits heterologous fusion in a carbohydrate dependent
manner. The galectin-1 effect of fusion inhibition was abrogated
by addition of the cognate disaccharide lactose, but not by sucrose.
In both panels, data are the mean + S.D. of a representative
experiment performed in triplicate.
Found at: doi:10.1371/journal.ppat.1000993.s001 (0.05 MB TIF)
Figure S2 MALDI-TOF mass spectrum of permethylated N-
glycans from NiV-F1. Data were acquired in the positive ion mode
and all molecular ions are [M+Na]
+. Peaks labeled with *
represent contaminating hexose polymers. Peak assignments are
Gal-1 Inhibits NiV-F Mediated Endothelial Cell Fusion
PLoS Pathogens | www.plospathogens.org 12 July 2010 | Volume 6 | Issue 7 | e1000993based on theoretical compositions together with knowledge of the
biosynthetic pathways. Symbol nomenclature is that used
employed by the Consortium for Functional Glycomics (CFG)
for the representation of glycan structures. Key: Galactose (yellow
circle), Mannose (green circle), GlcNAc (blue square), Fucose (red
triangle), NeuAc, (purple diamond).
Found at: doi:10.1371/journal.ppat.1000993.s002 (0.32 MB TIF)
Figure S3 The structure of the glycans found at the F5
glycosylation site. The table shows the glycan compositions of
the glycopeptide, VDISSQISSMNQSLQQSK, observed as
doubly, triply and quadruply charged molecular ion signals in
the MS data summed between the ion retention times 51.8–
52.9 min (data not shown). The m/z values in the table
correspond to the smallest isotope in each cluster and the Mr
values are calculated accordingly. Potential structures of the glycan
compositions are given, deduced by taking into account prior
glycomic experimental data and knowledge of the biosynthetic
pathways. Key: Galactose (yellow circle), Mannose (green circle),
GlcNAc (blue square), Fucose (red triangle), NeuAc, (purple
diamond).
Found at: doi:10.1371/journal.ppat.1000993.s003 (0.65 MB TIF)
Figure S4 The structure of the glycans found at glycosylation
site, F4. The glycan compositions of the glycopeptide,
AISQSGTLLMIDNTTCPTAVLGNVIISLGK, observed as dou-
bly, triply and quadruply charged molecular ion signals in the MS
data summed between the ion retention times 84.7–86.8 min (data
not shown). Key: Galactose (yellow circle), Mannose (green circle),
GlcNAc (blue square), Fucose (red triangle), NeuAc, (purple
diamond).
Found at: doi:10.1371/journal.ppat.1000993.s004 (0.81 MB TIF)
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